Traders should monitor the April 20, 2026 spin-off date and the execution of the $100M buyback, which could support ANAB stock. The market may re-rate Anaptys as a royalty vehicle, but execution risk around the separation and reliance on external partnerships (GSK, Vanda) remains.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 27 $38.27entry
- T+1 · 8mo ago −3.50%α −3.14% · $36.93
- T+5 · 8mo ago +8.76%α +4.90% · $41.62
- T+20 · 7mo ago +74.02%α +61.27% · $66.59
- T+60 · 5mo ago +53.87%α +37.80% · $58.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured $80 million in gross proceeds from a $145 million private placement. Concurrently, Anaptys announced a $100 million stock repurchase plan and a lean post-spin-off structure focused on managing royalty assets with minimal operating expenses.
Key Financial Metrics
Key Facts
- First Tracks Bio raised $80 million in gross proceeds from the sale of 5,791,478 shares at $13.81 per share in a private placement.
- The spin-off of First Tracks Bio is expected to close on April 20, 2026.
- Anaptys will retain ~$140–145 million in net cash and investments post-spin-off and operate with less than 10 FTEs and under $10M annual operating expenses.
- Anaptys announced a $100 million stock repurchase plan effective after March 31, 2026, expiring December 31, 2026.
- Susannah Gray, former CFO of Royalty Pharma, has been appointed to Anaptys’ board to support its royalty-focused strategy.
Financial Impact
$80 million raised by First Tracks Bio; $100 million buyback authorized by Anaptys; Anaptys to retain $140–145 million in cash and investments
Risk Factors
- Spin-off may not close as planned, delaying or altering capital return and structure.
- Anaptys’ future value depends entirely on third-party royalty performance (GSK, Vanda), introducing external execution risk.
- Limited transparency on how buyback will be executed; could be slow or market-dependent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263788 |
| PRESS-RELEASE Data (Synthetic) | press-3263790 |
Track record
28 reports on ANAB
10 of 19 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 13 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers